BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23235179)

  • 1. [Modified FOLFOX6(mFOLFOX6)in metastatic colorectal carcinoma patients with poor performance status].
    Nishi T; Hamamoto Y; Uemoto J; Onodera K; Warita E; Yamanaka Y
    Gan To Kagaku Ryoho; 2012 Dec; 39(13):2557-60. PubMed ID: 23235179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic effect of mFOLFOX6 for synchronous unresectable liver metastases from colorectal cancer].
    Chikatani K; Ishibashi K; Tajima Y; Hatano S; Amano K; Ishiguro T; Kuwabara K; Sobajima J; Ohsawa T; Okada N; Kumamoto K; Haga N; Iwama T; Ishida H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2211-3. PubMed ID: 22202333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
    Matsumoto S; Nishimura T; Kanai M; Mori Y; Nagayama S; Kawamura J; Nomura A; Miyamoto S; Kitano T; Ishiguro H; Yanagihara K; Teramukai S; Sakai Y; Chiba T; Fukushima M
    Chemotherapy; 2008; 54(5):395-403. PubMed ID: 18781065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
    Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
    Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical outcome of mFOLFOX6 treatment for colorectal cancer patients who underwent resection of liver metastasis -comparison between synchronous and metachronous liver metastasis].
    Honjou H; Ishibashi K; Okada N; Tajima Y; Ishiguro T; Kuwabara K; Ohsawa T; Kumamoto K; Tsuji Y; Haga N; Iwama T; Ishida H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2216-9. PubMed ID: 22202335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.
    Yoshino T; Yamazaki K; Hamaguchi T; Shimada Y; Kato K; Yasui H; Boku N; Lechuga MJ; Hirohashi T; Shibata A; Hashigaki S; Li Y; Ohtsu A
    Anticancer Res; 2012 Mar; 32(3):973-9. PubMed ID: 22399619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study.
    Nagata N; Kondo K; Kato T; Shibata Y; Okuyama Y; Ikenaga M; Tanemura H; Oba K; Nakao A; Sakamoto J; Mishima H
    Hepatogastroenterology; 2009; 56(94-95):1346-53. PubMed ID: 19950789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer].
    Ishiguro T; Ishibashi K; Okada N; Kuwabara K; Miyazaki T; Yokoyama M; Matsuki M; Sano M; Inoue N; Ishida H
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2286-8. PubMed ID: 19106598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
    Shimizu T; Satoh T; Tamura K; Ozaki T; Okamoto I; Fukuoka M; Nakagawa K
    Int J Clin Oncol; 2007 Jun; 12(3):218-23. PubMed ID: 17566846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients].
    Kuboki Y; Ichimura T; Ogura M; Matsuda M; Suenaga M; Shinozaki E; Matsuzaka S; Chin K; Mizunuma N; Hatake K
    Gan To Kagaku Ryoho; 2008 May; 35(5):781-5. PubMed ID: 18487913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603.
    Kanemitsu Y; Kato T; Shimizu Y; Inaba Y; Shimada Y; Nakamura K; Sato A; Moriya Y;
    Jpn J Clin Oncol; 2009 Jun; 39(6):406-9. PubMed ID: 19389795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recurrance of disappearing colorectal liver metastases after mFOLFOX6 regimen].
    Ono T; Okada N; Kumamoto K; Ishibashi K; Haga N; Ishida H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2214-5. PubMed ID: 22202334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
    Innominato PF; Giacchetti S; Moreau T; Smaaland R; Focan C; Bjarnason GA; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Lévi F;
    Chronobiol Int; 2011 Aug; 28(7):586-600. PubMed ID: 21859417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction].
    Ueda H; Demizu M; Oosawa M; Chihara S; Nakanishi Y; Maeda C; Yano K; Kimura F; Iwakawa S
    Gan To Kagaku Ryoho; 2009 May; 36(5):789-93. PubMed ID: 19461179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion of colorectal cancer].
    Ishibashi K; Okada N; Tajima Y; Ishiguro T; Kuwabara K; Ohsawa T; Kumamoto K; Tsuji Y; Haga N; Iwama T; Ishida H; Onouchi T; Yakabi K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2220-3. PubMed ID: 22202336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer].
    Matoba S; Sawada T; Toda S; Moriyama J; Yokoyama T; Ehara K; Mine S; Ueno M; Kinoshita Y; Matsuda M; Tsutsumi K; Hashimoto M; Udagawa H; Watanabe G; Katori H; Hayashi M; Igarashi M; Ito T; Hasebe S; Sato M
    Gan To Kagaku Ryoho; 2008 Apr; 35(4):673-5. PubMed ID: 18408443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
    Kawakami H; Satoh T; Nakagawa K
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001
    [No Abstract]   [Full Text] [Related]  

  • 20. Multi-center phase II study of FLOX for advanced colorectal cancer patients in Japan: SWIFT 3 study.
    Kato T; Nagata N; Fujii M; Takemoto H; Kondo K; Okuyama Y; Tominaga H; Sakamoto J; Mishima H
    Anticancer Res; 2011 Dec; 31(12):4657-64. PubMed ID: 22199346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.